TY  - JOUR
TI  - Role of sodium glucose cotransporter-2 (SGLT2) inhibitors in the modulation of QTc interval and ventricular arrhythmia in patients with diabetes mellitus combined with hypertension and coronary artery disease
AU  - Liu, Jia
AU  - Shi, Yinglin
AU  - Zhang, Yuan
AU  - Wang, Xin
AU  - Zhu, Xiaoming
JO  - Pakistan Journal of Pharmaceutical Sciences
JA  - Pak. J. Pharm. Sci.
VL  - 39
IS  - 5
SP  - 1538
EP  - 1551
PY  - 2026
DA  - 2026/05
KW  - Coronary artery disease
KW  - Diabetes
KW  - Hypertension
KW  - QTc interval
KW  - Sodium glucose cotransporter 2 inhibitor
KW  - Ventricular arrhythmia
DO  - 10.36721/PJPS.2026.39.5.REG.15600.1
AB  - Background: Patients with diabetes mellitus combined with hypertension and coronary artery disease (DM-HTN-CAD) are prone to QTc interval prolongation and ventricular arrhythmias. Although sodium glucose cotransporter-2 (SGLT2) inhibitors have hypoglycemic and cardioprotective effects, their regulatory influence on these indicators requires further clarification. Objectives: This study evaluated the impact of SGLT2 inhibitors on QTc interval and ventricular arrhythmia in patients with DM-HTN-CAD. Methods: From January 2023 to January 2025, 150 patients with DM-HTN-CAD were enrolled and divided into conventional treatment and SGLT2 inhibitor groups. The SGLT2 inhibitor group received SGLT2 inhibitors in addition to standard therapy. Primary indicators included QTc interval, echocardiographic parameters (ventricular and atrial diameters and ejection fraction), blood pressure and glucose indicators. Secondary outcomes included quality of life scores, complications and adverse reactions. Results: Baseline characteristics were comparable between groups (P>0.05). After treatment, both groups showed improvements, but the SGLT2 inhibitor group had significantly lower QTc intervals, atrial and ventricular diameters, systolic and diastolic blood pressure and fasting blood glucose levels. Left ventricular ejection fraction, quality of life scores and overall clinical response rates were significantly higher, while complication and adverse reaction rates were lower compared with the conventional therapy group (P<0.05). Conclusion: SGLT2 inhibitors effectively shorten QTc interval, reduce ventricular arrhythmia risk and improve cardiovascular outcomes in DM-HTN-CAD patients with good safety profiles.
ER  -